Don't withhold anti-neoplastic treatment from your hematological patients infected by COVID [MDS Professional Report]

PAPER 1Authors: Vijenthira A. et al. (Princess Margaret, Toronto)Title: Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patientsDescription:⦁ About a third of hospitalized adult patients with hematologic malignancy and COVID-19 – dye. ⦁ No need to withhold anti-cancer treatment from these patients.
Paper 2Authors: P. Fenaux; U. Platzbecker; A. List and colleagues, multicenterTitle: Luspatercept in Patients with Lower-Risk Myelodysplastic SyndromesDescription: Luspatercept, an activin receptor derived agent, improves the anemia in LR-MDS patients. Thus, we have another approved anti-anemic agent in addition to ESAs for these patients.
Paper 3Authors: David Henry et al. , multicenter ((Disclosure – I am a co-author)Title: Oral Roxadustat Demonstrates Efficacy in Anemia Secondary to Lower-Risk Myelodysplastic Syndrome Irrespective of Ring Sideroblasts and Baseline Erythropoietin LevelsDescription: Roxadustat, an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, is another investigated effective agent for the anemia in LR-MDS.
Paper 4Title: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AMLAuthors: M.A. Sekeres, and colleagues, multicenter, multunationalDescription: Pevonedistat, a NEDD8 inhibitor, together with azacitidine, improves the response and prognosis in HR-MDS patients.